Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grifols, S.A.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Spain’s Grifols Takes Restructuring Route After COVID Challenges
The Barcelona-based company is making major cuts to its headcount in a bid to save €400m and support its operational recovery after the significant impact of the pandemic to Grifol’s plasma business.
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- Talecris Biotherapeutics Inc.
- Haema AG.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.